by Frank L. Ward, Rohan John, Joanne M. Bargman, Rory F. McQuillan
American Journal of Kidney Diseases / 2016-11-14 18:08
Preapproval clinical trials examining the safety and efficacy of rosuvastatin demonstrated an increased incidence of proteinuria, hematuria, rhabdomyolysis, and other acute kidney injury of unknown cause at high doses. The latter cases manifested with urine sediment findings and in some cases, renal histology, indicating renal tubular injury in the absence of rhabdomyolysis. Despite these provocative findings, there have been very few reports in the literature regarding non−rhabdomyolysis-mediated acute kidney injury associated with high-dose rosuvastatin since its widespread introduction more than a decade ago, suggesting that it is either a rare entity or systematically underdiagnosed and under-reported.
-- Shared via Inoreader
Enviado desde mi iPhone
No comments:
Post a Comment